Log in

Relevant bibliographies by topics / Microangiopathic Anemia / Journal articles

To see the other types of publications on this topic, follow the link: Microangiopathic Anemia.

Journal articles on the topic 'Microangiopathic Anemia'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Microangiopathic Anemia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Brocklebank, Vicky, Katrina M. Wood, and David Kavanagh. "Thrombotic Microangiopathy and the Kidney." Clinical Journal of the American Society of Nephrology 13, no. 2 (2017): 300–317. http://dx.doi.org/10.2215/cjn.00620117.

Full text

Abstract:

Thrombotic microangiopathy can manifest in a diverse range of diseases and is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ injury, including AKI. It can be associated with significant morbidity and mortality, but a systematic approach to investigation and prompt initiation of supportive management and, in some cases, effective specific treatment can result in good outcomes. This review considers the classification, pathology, epidemiology, characteristics, and pathogenesis of the thrombotic microangiopathies, and outlines a pragmatic approach to diagnosis and

APA, Harvard, Vancouver, ISO, and other styles

2

Bhawna, Gondwal. "Thrombotic Microangiopathic Haemolytic Anaemia: A Pathologic Abnormality Associated with Diverse Clinical Syndromes." British Journal of BioMedical Research 1, no. 4 (2017): 217–22. https://doi.org/10.24942/bjbmr.2017.165.

Full text

Abstract:

A pathological process of microvascular thrombosis, microangiopathic hemolytic anemia and thrombocytopenia, with ischemia and infraction, affecting particularly kidney and brain is Thrombotic microangiopathy  (TMA). Disseminated intravascular coagulation (DIC) is caused by severe infectious disease and systemic inflammatory syndrome (SIRS). Thrombotic microangiopathy  (TMA) a rare but devastating disease, also known as microangiopathic hemolytic anemia (MAHA) in combination with thrombocytopenia and signs of organ damage. These pathological features are included in different clinical

APA, Harvard, Vancouver, ISO, and other styles

3

Todorović, Željko, and Marko Anđelić. "Thrombotic microangiopathy as the first manifestation of disseminated malignant disease." Srpski medicinski casopis Lekarske komore 3, no. 4 (2022): 492–98. http://dx.doi.org/10.5937/smclk3-40946.

Full text

Abstract:

Introduction: Thrombotic microangiopathies are a group of diseases characterized by disseminated intravascular thrombosis, thrombocytopenia and ischemic organ damage. This group includes thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. One of the causes of thrombotic microangiopathy, although rare, can also be malignant diseases, primarily cancers of the stomach, prostate, breast and lungs. Case report: We present a patient with thrombotic microangiopathy and disseminated malignant disease of unclear etiology. Conclusion: This clinical entity is called carcinoma-associated th

APA, Harvard, Vancouver, ISO, and other styles

4

Ikushima, Eigo, Manabu Hisahara, Takuya Nishijima, et al. "Atypical Hemolytic Uremic Syndrome following Acute Type A Aortic Dissection." Case Reports in Hematology 2020 (March 4, 2020): 1–4. http://dx.doi.org/10.1155/2020/2467953.

Full text

Abstract:

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA)-related disease that manifests as a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI) and is caused by uncontrolled activation of the complement system. We report the case of a 61-year-old woman with acute type A aortic dissection that subsequently developed into aHUS. The hematologic disorders underlying aHUS improved after treatment with the complement inhibitor eculizumab. It is important to consider aHUS when a patient clinically develops a triad of microangiopathic hem

APA, Harvard, Vancouver, ISO, and other styles

5

Wasekar, Nilesh, and Shivani Joshi. "Interesting cases of microangiopathic hemolytic anemia." Medicover Journal of Medicine 1, no. 4 (2024): 172–75. https://doi.org/10.4103/mjm.mjm_38_24.

Full text

Abstract:

Microangiopathic hemolytic anemia (MAHA) is a type of hemolytic anemia where there is fragmentation and hemolysis due to damage of erythrocytes in the small blood vessels. The initial evaluation is focused on confirming MAHA and thrombocytopenia and excluding systemic disorders that manifest these findings/mimic thrombotic thrombocytopenic purpura. All patients with a suspected primary thrombotic microangiopathy should have a thorough laboratory workup. ADAMTS13 activity is measured before starting therapeutic plasma exchange (TPE). The immediate management decision is whether to perform TPE o

APA, Harvard, Vancouver, ISO, and other styles

6

Lee, Eric H., Salman Otoukesh, Amir Abdi pour, and Gayathri Nagaraj. "Hemolytic Anemia of Malignancy: A Case Study Involving Signet Ring Cell Metastatic Breast Cancer with Severe Microangiopathic Hemolytic Anemia." Case Reports in Oncology 12, no. 1 (2019): 104–8. http://dx.doi.org/10.1159/000494753.

Full text

Abstract:

Hemolytic anemia in the setting of malignancy is a rare manifestation of paraneoplastic syndrome with significant morbidity. Here we discuss a case involving metastatic breast cancer presenting with severe hemolytic anemia and renal failure secondary to thrombotic microangiopathy of malignancy. This case discusses the workup for secondary hemolytic anemia, a possible role for therapeutic plasma exchange in this setting, as well the current understanding of the management of microangiopathic hemolytic anemia of malignancy.

APA, Harvard, Vancouver, ISO, and other styles

7

Tulai, Iulia M., Oana M. Penciu, Raymond Raut, and Alla Rudinskaya. "Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy." Texas Heart Institute Journal 46, no. 1 (2019): 48–52. http://dx.doi.org/10.14503/thij-17-6472.

Full text

Abstract:

Thrombotic microangiopathic syndromes are characterized by thrombus formation leading to microangiopathic hemolytic anemia, thrombocytopenia, and end-organ injury that most often affects the kidney and brain. Patients with thrombotic microangiopathy can also present with cardiac involvement, which has been shown to worsen their prognosis. We describe the case of a 46-year-old woman who presented with acute congestive heart failure as a manifestation of catastrophic antiphospholipid syndrome, which is characterized by rapidly progressing multiorgan involvement. Targeted therapy improved our pat

APA, Harvard, Vancouver, ISO, and other styles

8

Skwierawska, Kamila, Krzysztof Woźniak, Anna Waszczuk-Gajda, et al. "Cancer-related microagiopathic hemolytic anemia in a patient with breast cancer – diagnostic difficulties." OncoReview 10, no. 4(40) (2020): 134–38. http://dx.doi.org/10.24292/01.or.420231220.

Full text

Abstract:

Cancer-related microangiopathic hemolytic anemia is rarely recognized as a paraneoplastic syndrome with a very poor prognosis in cancer patients. The treatment and prognosis are significantly different from that in other thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. The case of described patient demonstrates the diagnostic difficulties in diagnosing the causes of hemolytic anemia in patient with breast cancer and appropriate treatment.

APA, Harvard, Vancouver, ISO, and other styles

9

Özsoylu, Şinasi. "About Microangiopathic Hemolytic Anemia." Turkish Journal of Hematology 32, no. 1 (2015): 92. http://dx.doi.org/10.4274/tjh.2014.0382.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Morton, Jordan M., and James N. George. "Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer." Journal of Oncology Practice 12, no. 6 (2016): 523–30. http://dx.doi.org/10.1200/jop.2016.012096.

Full text

Abstract:

The unexpected occurrence of thrombotic microangiopathy (TMA), characterized by microangiopathic hemolytic anemia and thrombocytopenia, in a patient with cancer requires urgent diagnosis and appropriate management. TMA is a term used to describe multiple syndromes caused by microvascular thrombosis, including thrombotic thrombocytopenic purpura (TTP), Shiga toxin–mediated hemolytic uremic syndrome, and complement-mediated TMA. In patients with cancer, systemic microvascular metastases and bone marrow involvement can cause microangiopathic hemolytic anemia and thrombocytopenia. This occurs most

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Thrombotic Angiopathy (Microangiopathic Hemolytic Anemia)." Emergency Medicine News 26, no. 2 (2004): 25. http://dx.doi.org/10.1097/00132981-200402000-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lechner, Klaus, and Hanna Lena Obermeier. "Cancer-Related Microangiopathic Hemolytic Anemia." Medicine 91, no. 4 (2012): 195–205. http://dx.doi.org/10.1097/md.0b013e3182603598.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Salhab, Mohammed, Andrew Hsu, Elizabeth Ryer, Juliet Appiah, and Bradley Switzer. "Microangiopathic hemolytic anemia in pregnancy." Transfusion and Apheresis Science 56, no. 3 (2017): 354–56. http://dx.doi.org/10.1016/j.transci.2017.02.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Neave, Lucy, and Marie Scully. "Microangiopathic Hemolytic Anemia in Pregnancy." Transfusion Medicine Reviews 32, no. 4 (2018): 230–36. http://dx.doi.org/10.1016/j.tmrv.2018.08.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Schiller, D. "Malignancy-associated microangiopathic hemolytic anemia." Journal of Clinical Oncology 15, no. 6 (1997): 2474–75. http://dx.doi.org/10.1200/jco.1997.15.6.2474.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Choy, Bonnie, Juliana Alvarez Argote, and Angela Treml. "Cancer-related microangiopathic hemolytic anemia." Transfusion 56, no. 8 (2016): 1937. http://dx.doi.org/10.1111/trf.13634.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Bain, Barbara J., and Emma Fosbury. "Microangiopathic hemolytic anemia with hyposplenism." American Journal of Hematology 84, no. 4 (2009): 242. http://dx.doi.org/10.1002/ajh.21301.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Nlandu, Yannick, Franck Pourcine, Ly van phach Vong, et al. "Cabazitaxel Induced Thrombotic Microangiopathy in a Patient with Prostate Cancer." Case Reports in Nephrology 2019 (November 19, 2019): 1–3. http://dx.doi.org/10.1155/2019/8591283.

Full text

Abstract:

Cancer-associated thrombotic microangiopathy (TMA) refers to a group of disorders characterized by microangiopathic haemolytic anemia, thrombocytopenia, and ischemic organ damage. TMA manifestations can be induced by cancer or by chemotherapy. We report the case of a 64-year-old man with metastatic prostate cancer who experienced a Cabazitaxel-induced TMA manifestation. TMA responds to conservative therapy, dialysis without plasmaphoresis, with progressive recovered renal function.

APA, Harvard, Vancouver, ISO, and other styles

19

Adhitya Surya, S. "A Rare Encounter: Microangiopathic Hemolytic Anemia - A Case Report." International Journal of Science and Research (IJSR) 13, no. 5 (2024): 1582–85. http://dx.doi.org/10.21275/sr24524062148.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Hassan, HassanainHani, and LiqaaMohammed Al-Shareefy. "The challenge of microangiopathic hemolytic anemia." Iraqi Journal of Hematology 6, no. 1 (2017): 24. http://dx.doi.org/10.4103/ijh.ijh_9_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Alonso-Santor, Juan E., José L. Gutierrez-Zufiaurre, and José L. Pérez-Castrillón. "Microangiopathic hemolytic anemia secondary to cyclosporine." Annals of Pharmacotherapy 38, no. 5 (2004): 903. http://dx.doi.org/10.1345/aph.1d123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Chatiwala, J., M. Maroules, and A. Karippot. "Malignant hemangioendothelioma and microangiopathic hemolytic anemia." Journal of Clinical Oncology 26, no. 15_suppl (2008): 21520. http://dx.doi.org/10.1200/jco.2008.26.15_suppl.21520.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Stratta, Piero, Caterina Canavese, and Antonio Vercellone. "Hellp, Microangiopathic Hemolytic Anemia, and Preeclampsia." Hypertension in Pregnancy 12, no. 3 (1993): 487–96. http://dx.doi.org/10.3109/10641959309042867.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Walker, Russell W., Marc K. Rosenblum, Sanford J. Kempin, and Michaele C. Christian. "Carboplatin-associated thrombotic microangiopathic hemolytic anemia." Cancer 64, no. 5 (1989): 1017–20. http://dx.doi.org/10.1002/1097-0142(19890901)64:5<1017::aid-cncr2820640508>3.0.co;2-n.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Upalakalin, J. Nalinee, Lynne Uhl, and Andrew J. Burger. "Mitral valve‐induced microangiopathic hemolytic anemia." Transfusion 42, no. 9 (2002): 1105. http://dx.doi.org/10.1046/j.1537-2995.2002.00211.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Valbonesi, M., U. Valente, R. Pellicci, et al. "Thrombotic Microangiopathy of the Miscellaneous Secondary Type Responding to Plasma Exchange in a Liver Transplant Recipient." International Journal of Artificial Organs 11, no. 2 (1988): 131–33. http://dx.doi.org/10.1177/039139888801100214.

Full text

Abstract:

A thrombotic microangiopathy syndrome, clinically and pathologically similar to thrombotic thrombocytopenic purpura (TTP) has been reported in recipients of tissue transplants, including renal and bone marrow allografts. The diagnosis is made only after other causes of microangiopathic hemolytic anemia have been excluded. In this case report we present the outcome of the combination of plasma exchange, dipyridamole and aspirin in the management of a TTP-like syndrome that complicated the post-operative course of liver transplantation.

APA, Harvard, Vancouver, ISO, and other styles

27

Azmaiparashvili, Zurab, Vinicius M. Jorge, and Catiele Antunes. "An Atypical Presentation of Chronic Atrophic Gastritis: Hemolytic Anemia and Mesenteric Panniculitis." Case Reports in Hematology 2017 (2017): 1–5. http://dx.doi.org/10.1155/2017/5498034.

Full text

Abstract:

Microangiopathic hemolytic anemia (MAHA) requires an aggressive approach since primary thrombotic microangiopathy syndromes such as thrombotic thrombocytopenic purpura (TTP) can progress rapidly to a fatal outcome. Differential diagnosis can be challenging even for an experienced hematologist. We present a case of a 52-year-old male who presented with symptoms of mesenteric panniculitis and showed signs of MAHA. His condition was attributed to severe vitamin B12 deficiency secondary to chronic atrophic gastritis and initiation of appropriate therapy was met with complete resolution of symptoms

APA, Harvard, Vancouver, ISO, and other styles

28

Radhi, Mohamed, and Shannon L. Carpenter. "Thrombotic Microangiopathies." ISRN Hematology 2012 (July 25, 2012): 1–8. http://dx.doi.org/10.5402/2012/310596.

Full text

Abstract:

Thrombotic microangiopathy results from thrombotic occlusion of the microvasculature leading to fragmentation of red blood cells, profound thrombocytopenia, and a microangiopathic hemolytic anemia with elevation of lactate dehydrogenase and negative direct Coomb’s test. This constellation of clinical and laboratory findings is not due to one disease entity; rather, it represents a variety of underlying diagnoses. Among the major disease entities are TTP/HUS, which can be congenital or acquired, bacterial infections, medications, vascular or endothelial pathology like Kasabach-Merritt phenomeno

APA, Harvard, Vancouver, ISO, and other styles

29

Conway, Edward M. "HUS and the case for complement." Blood 126, no. 18 (2015): 2085–90. http://dx.doi.org/10.1182/blood-2015-03-569277.

Full text

Abstract:

Abstract Hemolytic-uremic syndrome (HUS) is a thrombotic microangiopathy that is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. Excess complement activation underlies atypical HUS and is evident in Shiga toxin–induced HUS (STEC-HUS). This Spotlight focuses on new knowledge of the role of Escherichia coli–derived toxins and polyphosphate in modulating complement and coagulation, and how they affect disease progression and response to treatment. Such new insights may impact on current and future choices of therapies for STEC-HUS.

APA, Harvard, Vancouver, ISO, and other styles

30

Khoo, Jing Y., Mark L. Lessne, and Vani V. Gopalareddy. "Microangiopathic Hemolytic Anemia Following Transjugular Intrahepatic Portosystemic Shunt Creation in an Adolescent." ACG Case Reports Journal 12, no. 5 (2025): e01685. https://doi.org/10.14309/crj.0000000000001685.

Full text

Abstract:

ABSTRACT Transjugular intrahepatic portosystemic shunt (TIPS) creation is an effective approach to address the complications of portal hypertension. This case report describes an adolescent boy who underwent TIPS creation with an expanded polytetrafluorethylene-lined stent graft for portal hypertension secondary to sinusoidal obstruction syndrome. He subsequently developed microangiopathic hemolytic anemia, an uncommon complication of covered stents that is not well reported in the pediatric population. Despite its rarity and typical conservative management, microangiopathic hemolytic anemia s

APA, Harvard, Vancouver, ISO, and other styles

31

Al-Mendalawi, MahmoodDhahir. "Malignancy-associated microangiopathic hemolytic anemia and thrombocytopenia." Indian Journal of Medical and Paediatric Oncology 40, no. 4 (2019): 594. http://dx.doi.org/10.4103/ijmpo.ijmpo_111_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Abdulla, MansoorC, Jemshad Alungal, LekhaK Nair, and Mohthash Musambil. "Malignancy associated microangiopathic hemolytic anemia and thrombocytopenia." Indian Journal of Medical and Paediatric Oncology 39, no. 2 (2018): 254. http://dx.doi.org/10.4103/ijmpo.ijmpo_128_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Abdulla, MansoorC, Jemshad Alungal, BabithaAlingal Mohammed, and Mohammed Salih. "Microangiopathic hemolytic anemia in active ulcerative colitis." Journal of Applied Hematology 7, no. 4 (2016): 152. http://dx.doi.org/10.4103/1658-5127.198513.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Raina, Rupesh, Charbel Salem Saul Nurko, and Titte Srinivas. "244: Microangiopathic Hemolytic Anemia Complicating Renal Transplant." American Journal of Kidney Diseases 55, no. 4 (2010): B92. http://dx.doi.org/10.1053/j.ajkd.2010.02.251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Basit Momin, MajedAbdul, SarojKumar Prusty, Anamika Aluri, and V. Soumya. "Fatal microangiopathic hemolytic anemia: Two case reports." Journal of the Scientific Society 45, no. 1 (2018): 36. http://dx.doi.org/10.4103/jss.jss_9_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Lofaro, Thomas, and Barbara J. Bain. "Schistocytosis is not always microangiopathic hemolytic anemia." American Journal of Hematology 95, no. 11 (2020): 1421–22. http://dx.doi.org/10.1002/ajh.25861.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Podzamczer, D. "Microangiopathic hemolytic anemia associated with pulmonary adenocarcinoma." JAMA: The Journal of the American Medical Association 254, no. 18 (1985): 2554–55. http://dx.doi.org/10.1001/jama.254.18.2554.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Mach-Pascual, Sara, Kaveh Samii, and Photis Beris. "Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy." American Journal of Hematology 52, no. 4 (1996): 310–12. http://dx.doi.org/10.1002/(sici)1096-8652(199608)52:4<310::aid-ajh11>3.0.co;2-h.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Podzamczer, D. "Microangiopathic Hemolytic Anemia Associated With Pulmonary Adenocarcinoma." JAMA: The Journal of the American Medical Association 254, no. 18 (1985): 2554. http://dx.doi.org/10.1001/jama.1985.03360180052013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Heo, Min Hee, Jung Hyeon Kim, and Ji Yeon Kim. "Postoperative Thrombotic Microangiopathy with the Combined Administration of Tranexamic Acid and Batroxobin: Two Case Reports." Soonchunhyang Medical Science 27, no. 1 (2021): 16–19. http://dx.doi.org/10.15746/sms.21.004.

Full text

Abstract:

Thrombotic microangiopathy (TMA) is a clinical syndrome characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end-organ damage. When TMA is suspected, accurate diagnosis is required; however, differential diagnosis is often difficult because each patient has various clinical features, and the causes of triggers may overlap. We report two cases of TMA that developed after surgeries in patients, with the combined administration of tranexamic acid and batroxobin intraoperatively. We need to consider the risk of adverse effects of the concomitant use of tranexamic acid and batr

APA, Harvard, Vancouver, ISO, and other styles

41

Weitz, Ilene Ceil. "Thrombotic Microangiopathy in Cancer." Seminars in Thrombosis and Hemostasis 45, no. 04 (2019): 348–53. http://dx.doi.org/10.1055/s-0039-1687893.

Full text

Abstract:

AbstractThrombotic microangiopathy (TMA) is a rare but often devastating complication of cancer and cancer treatment. The syndrome is defined by thrombocytopenia (i.e., a platelet count of < 150,000/mcL or > 30% decrease from baseline), microangiopathic hemolytic anemia, and some evidence of organ damage. Among the nine recognized groups of disorders causing TMA, the focus of this article will be on cancer and cancer treatment-related causes of TMA. This review will discuss the pathophysiology of TMA in cancer, chemotherapy-associated TMA, transplant-associated TMA, and newer therapeutic

APA, Harvard, Vancouver, ISO, and other styles

42

Lúcio, Donavan de Souza, Jacqueline Foelkel Pignatari, Marcelo Gil Cliquet, and Henri Augusto Korkes. "Relapse of congenital thrombotic thrombocytopenic purpura, after spontaneous remission, in a second-trimester primigravida: case report and review of the literature." Sao Paulo Medical Journal 135, no. 5 (2017): 491–96. http://dx.doi.org/10.1590/1516-3180.2016.0188201116.

Full text

Abstract:

ABSTRACT CONTEXT: Thrombotic microangiopathy syndrome or thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) describes distinct diseases sharing common pathological features: microangiopathic hemolytic anemia and thrombocytopenia, without any other apparent cause. CASE REPORT: An 18-year-old second-trimester primigravida presented with a history of fifteen days of intense weakness, followed by diarrhea over the past six days. She reported having had low platelets since childhood, but said that she had never had bleeding or menstrual abnormalities. Laboratory investigation s

APA, Harvard, Vancouver, ISO, and other styles

43

Cantrell, J. E., T. M. Phillips, and P. S. Schein. "Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy." Journal of Clinical Oncology 3, no. 5 (1985): 723–34. http://dx.doi.org/10.1200/jco.1985.3.5.723.

Full text

Abstract:

A thrombotic microangiopathy resembling the hemolytic uremic syndrome was diagnosed in 12 patients with adenocarcinoma, in whom the tumor was in complete or near-complete remission after treatment with mitomycin C-containing drug regimens. Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure were initially present in all cases. All patients eventually developed pulmonary edema and systemic arterial hypertension, and three experienced neurologic complications. Blood transfusions exacerbated the syndrome in nine patients. High titers of platelet-aggregating plasma immune comple

APA, Harvard, Vancouver, ISO, and other styles

44

Gautam, Prerana, Ishwor Man Singh, Bimas Payangu Limbu, Monasha Vaidya, and Ujwal Rai. "Diagnostic Dilemma of Hemolytic Anemia: A Reveal Secondary to Gastric Adenocarcinoma." Medical Journal of Eastern Nepal 2, no. 01 (2023): 44–46. http://dx.doi.org/10.3126/mjen.v2i01.56222.

Full text

Abstract:

Here is a case report of a 62-year-old female who presented to our hospital with complaints of abdominal pain, unresolving severe anemia, bleeding per rectum with history of multiple blood transfusions at outside hospital. On initial investigations, the findings directed towards case of hemolytic anemia. The cause of hemolytic anemia was still unknown even after extensive clinical and laboratory investigations. Bone marrow biopsy was done, which revealed metastatic adenocarcinoma and diagnosis of cancer-related microangiopathic haemolytic anaemia (CR-MAHA) was established. Endoscopic biopsy wa

APA, Harvard, Vancouver, ISO, and other styles

45

Kandari, Sharon, Arshdeep Singh, Rohit Puri, Anil Cheriyan, and Sandeep Kaur. "A case report of thrombotic microangiopathy in a patient with advanced pancreatic carcinoma: an emerging, rare, and serious complication." International Journal of Advances in Medicine 12, no. 3 (2025): 308–10. https://doi.org/10.18203/2349-3933.ijam20251081.

Full text

Abstract:

Thrombotic microangiopathies are characterized by microangiopathic hemolytic anemia and end-organ damage following endothelial injury. The chemotherapeutic agents used in malignancy are one of the important causes of secondary TMA. Both malignancy and TMA are associated with significant morbidity and mortality. Timely recognition of both can result in early target-specific treatment initiation and better outcomes for both diseases. Here, we present a case of TMA in a patient with stage 4 pancreatic carcinoma being treated with Gemcitabine presented with acute kidney disease with new-onset hype

APA, Harvard, Vancouver, ISO, and other styles

46

Войцеховский, В. В., Л. Б. Филатов, А. В. Пивник, П. В. Авдонин, Т. В. Есенина та А. Г. Судаков. "Особенности диагностики и лечения тромботической тромбоцитопенической пурпуры, развившейся во время беременности: обзор литературы и собственное наблюдение". Clinical Oncohematology 7, № 4 (2014): 587–98. https://doi.org/10.21320/2500-2139-2014-7-4-587-598.

Full text

Abstract:

This paper presents a literature review on state of art in issues of etiology, pathogenesis, clinical features and diagnosis of thrombotic thrombocytopenic purpura (ТТP or Moschcowitz’s disease). Data on a rare pathology of congenital ТТP (Upshaw—Schulman syndrome) and its manifestation during pregnancy are summarized. Various aspects of differential diagnosis for microangiopathic hemolytic anemia (МАHA), complicated issues in differential diagnosis for thrombotic microangiopathies (ТТP, hemolytic uremic syndrome, HELLP syndrome) during pregnancy are discussed. Specificity of clinical manifest

APA, Harvard, Vancouver, ISO, and other styles

47

Das, Rhituparna, Saugat Dasgupta, Moumita Sengupta, and Keya Basu. "Three shades of black - secondary thrombotic microangiopathy." Indian Journal of Pathology and Microbiology 65, no. 4 (2022): 898–901. http://dx.doi.org/10.4103/ijpm.ijpm_1237_21.

Full text

Abstract:

Thrombotic microangiopathy is a group of disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia and organ damage. Wide age distribution and the heterogeneity in presentation demand a deeper understanding into the pathogenesis of TMA. Primary TMA is distinct from TMA associated with secondary causes and remains clinically occult till a precipitating factor aggravates it. The extent and severity of renal damage caused by each of them is also distinct. The first alerting signal could be the presence of schistiocytes on peripheral smear and arteriolar thrombi on light micro

APA, Harvard, Vancouver, ISO, and other styles

48

Thomas, M. R., and M. Scully. "How I treat microangiopathic hemolytic anemia in patients with cancer." Blood 137, no. 10 (2021): 1310–17. http://dx.doi.org/10.1182/blood.2019003810.

Full text

Abstract:

Abstract Microangiopathic hemolytic anemia (MAHA) with thrombocytopenia, suggests a thrombotic microangiopathy (TMA), linked with thrombus formation affecting small or larger vessels. In cancer patients, it may be directly related to the underlying malignancy (initial presentation or progressive disease), to its treatment, or a separate incidental diagnosis. It is vital to differentiate incidental thrombotic thrombocytopenia purpura or atypical hemolytic uremic syndrome in cancer patients presenting with a TMA, as they have different treatment strategies, and prompt initiation of treatment imp

APA, Harvard, Vancouver, ISO, and other styles

49

Rahman, Wan Suriana Wan Ab, Wan Zaidah Abdullah, Rapiaah Mustaffa, Suhair Abbas Ahmed, Mohd Nazri Hassan, and Azlan Husin. "Thrombotic Thrombocytopenic Purpura: Three Peripartum Cases and Diagnostic Challenges." Clinical Medicine Insights: Case Reports 6 (January 2013): CCRep.S12122. http://dx.doi.org/10.4137/ccrep.s12122.

Full text

Abstract:

Thrombotic thrombocytopenic purpura (TTP) is a medical emergency characterized by occlusive microangiopathy due to intravascular platelet aggregation. This event results in damage to the red blood cells (RBCs) known as microangiopathic hemolytic anemia (MAHA). Schistocytes are circulating fragments of damaged RBCs that have different morphological features including keratocytes, helmet cells, and spherocytes. It is critical to report even a small number of these abnormal RBCs in the peripheral blood and to be alert for the possible diagnosis of TTP, especially in unexplained anemia and thrombo

APA, Harvard, Vancouver, ISO, and other styles

50

Korkmaz, Serdal, Saadettin Kilickap, Hatice Terzi, and Mehmet Sencan. "Sunitinib-Induced Microangiopathic Hemolytic Anemia: A Case Report." Erciyes Tıp Dergisi/Erciyes Medical Journal 36, no. 2 (2014): 88–90. http://dx.doi.org/10.5152/etd.2014.7934.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!